Imidazopyrimidine compounds and uses thereof

US11673891B2 · kind B2 · utility

Assignees

• DANA-FARBER CANCER INSTITUTE, INC. · US
• Children's Medical Center Corporation · US

Inventors

• Ofer Levy · Afula, IL
• David J. Dowling · Watertown, US
• Francesco Borriello · Brookline, US
• David A. Scott · Newton, US
• Spencer E. Brightman · San Diego, US
• Frederic Feru · Fresnes, FR

Key dates

• Filing date: Nov 14, 2018
• Grant date: Jun 13, 2023
• Expiry date: Jul 28, 2039

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. The compounds described herein are used as enhancers and/or modifiers of an immune response (e.g., innate and/or adaptive immune response), and are useful in treating and/or preventing a disease, as adjuvants in a vaccine for the disease, (e.g., proliferative disease, inflammatory disease, autoimmune disease, infectious disease, or chronic disease), or as stand alone anti-infective or immune response modifying agents. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.